Human CEACAM-19 Antibody Summary
Met1-Gly157
Accession # Q7Z692
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of CEACAM-19 in HEK293 Human Cell Line Transfected with Human CEACAM-19 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with (A) human CEACAM-19 or (B) irrelevant protein, and eGFP was stained with Mouse Anti-Human CEACAM-19 Monoclonal Antibody (Catalog # MAB93971) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B). Quadrant markers were set based on Mouse IgG1 Isotype Control (MAB002). Staining was performed using our Staining Membrane-associated Proteins protocol.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CEACAM-19
Carcinoembryonic antigen-related cell adhesion molecule-19 (CEACAM-19), also known as CEA-like gene 1 (CEAL1), is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-19 consists of a 125 amino acid (aa) extracellular domain, a 21 aa helical transmembrane domain, and a 122 aa cytoplasmic domain (1,2). The extracellular domain contains an Ig-like domain as well as a glycosylation site, while the cytoplasmic domain is predicted to contain at least one immunoreceptor tyrosine-based activation motif (ITAM) (3,4). The extracellular domain of human CEACAM-19 shows 71%, 72%, and 78% aa identity to mouse, rat, and bovine CEACAM-19. The CEACAM family of proteins are involved in numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (5,6). CEACAM-19 expression has been identified in a wide range of tissues including prostate, uterus, fetal brain, mammary and adrenal glands, skeletal muscle, small intestine, and kidney (1). Human CEACAM-19 has been found to be overexpressed in BT-474, BT20, and T47D breast cancer cell lines as well as LNCaP prostate cancer cells, suggesting a role in tumor progression and metastasis (1,3, 7). The overexpression in breast cancer patients is associated with poor prognosis (7).
- Schorilas, A. et al. (2003) Gene 310:79.
- Estiar, M. et al. (2016) Clin Exp Med doi:10.1007/s10238-016-0442-1.
- Beauchemin, N. and Arabzadeh, A. (2013) Cancer Metastasis Rev 32 (3-4):643.
- Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
- Obrink, B. (1997) Curr Opin Cell Biol 9:616.
- Horst, AK. and Wagener, C. (2004) Handb Exp Pharmacol 283.
- Michaelidou, K. et al. (2013) Int J Oncol 42:1770.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CEACAM-19 Antibody
There are currently no reviews for this product. Be the first to review Human CEACAM-19 Antibody and earn rewards!
Have you used Human CEACAM-19 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
